Search
forLearn
5 / 801 resultslearn platycladus orientalis
learn APISCALP™
learn hibiscus
learn Capixyl
Research
5 / 182 resultsresearch Sensory innervation of the hairs of the rat hindlimb: A light microscopic analysis
Different types of hairs on a rat's hindlimb have varying levels and patterns of nerve innervation.
research Skin manifestations associated with systemic diseases – Part I
The conclusion is that early diagnosis of skin signs linked to diseases like Lupus, Dermatomyositis, and Rheumatoid Arthritis is crucial to prevent serious complications.
research Histopathologic Criteria for Follicular Differentiation
The document outlines criteria to identify and differentiate neoplasms based on follicular characteristics.
research Pharmacognostic evaluation of Sphagneticola calendulacea (L.) Pruski: Leaves
The evaluation of Creeping Daisy leaves found important characteristics and compounds that support its use in medicine.
research Case number 19th of perforating necrobiosislipoidica worldwide
The document reports the first case of a rare skin condition in Colombia, the 19th case worldwide.
Community Join
5 / 1000+ resultscommunity Pelage Recruiting Now for Phase 2
Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.
community $120 million Series B funding to Pelsge
Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.
community Track hairline of Pelage executives
Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community PP405 Update and My Take on Pelage
Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.